Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-303 in GPC3-expressing hepatocellular carcinoma
NCT06478693Phase 1Recruiting
- Sponsor
- Myeloid Therapeutics
- Start
- Jul 2024
- Primary completion
- Dec 2027
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, mRNA Therapeutics
- Countries
- 3
01
Overview
Phase 1, open-label trial of MT-303 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Myeloid Therapeutics. Primary endpoints: Adverse Events, Recommended Phase 2 Dose and 4 more. Started Jul 2024; status: recruiting.
02
Drugs
MT-303
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06478693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478693.